Literature DB >> 8357279

Experimental model of lead nephropathy. III. Continuous low-level lead administration.

F Khalil-Manesh1, H C Gonick, A H Cohen.   

Abstract

We sought to determine whether continuous low-level lead exposure (100 ppm lead acetate in drinking water) for periods of 1, 3, 6, 9, or 12 mo would produce adverse effects on kidney function or morphology in rats. Maximum blood lead levels in experimental animals were reached at 3 mo and averaged 29.4 +/- 4.1 micrograms/dl. Glomerular filtration rate, determined by single-injection 125I-iothalamate clearance, was found to be significantly increased above pair-fed controls at 1 and 3 mo, but it was normal at other time periods. Levels of urinary N-acetyl-beta-D-glucosaminidase exceeded levels found in controls at all time periods, except at 12 mo, when the normal increase with aging obscured differences between experimental animals and controls. In contrast, urinary ligandin (glutathione S transferase), a more specific marker of metal-associated proximal tubular injury, was normal at all time periods. Proximal tubular nuclear inclusion bodies were sparse and were observed only at 1 and 3 mo. There were no other pathological alterations in the kidneys, except at 12 mo, at which time mild tubular atrophy and interstitial fibrosis were seen. Therefore, low-level lead exposure in rats produced no significant changes in renal function and produced only mild alterations in renal morphology after 12 mo. The absence of changes in urinary ligandin accorded with the relative absence of morphological changes, whereas the observed increases in urinary N-acetyl-beta-D-glucosaminidase suggest that this enzyme may be an overly sensitive indicator of tubular injury.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8357279     DOI: 10.1080/00039896.1993.9940372

Source DB:  PubMed          Journal:  Arch Environ Health        ISSN: 0003-9896


  8 in total

1.  Associations of low-level urine cadmium with kidney function in lead workers.

Authors:  Virginia M Weaver; Nam-Soo Kim; Bernard G Jaar; Brian S Schwartz; Patrick J Parsons; Amy J Steuerwald; Andrew C Todd; David Simon; Byung-Kook Lee
Journal:  Occup Environ Med       Date:  2010-10-25       Impact factor: 4.402

2.  Blood lead and cadmium levels and renal function in Korean adults.

Authors:  Sungjin Chung; Jong Hee Chung; Sung Jun Kim; Eun Sil Koh; Hye Eun Yoon; Cheol Whee Park; Yoon Sik Chang; Seok Joon Shin
Journal:  Clin Exp Nephrol       Date:  2013-11-26       Impact factor: 2.801

3.  Urinary and blood cadmium and lead and kidney function: NHANES 2007-2012.

Authors:  Melanie C Buser; Susan Z Ingber; Nathan Raines; David A Fowler; Franco Scinicariello
Journal:  Int J Hyg Environ Health       Date:  2016-01-28       Impact factor: 5.840

4.  Associations of blood lead with estimated glomerular filtration rate using MDRD, CKD-EPI and serum cystatin C-based equations.

Authors:  June T Spector; Ana Navas-Acien; Jeffrey Fadrowski; Eliseo Guallar; Bernard Jaar; Virginia M Weaver
Journal:  Nephrol Dial Transplant       Date:  2011-01-19       Impact factor: 5.992

Review 5.  Renal effects of environmental and occupational lead exposure.

Authors:  M Loghman-Adham
Journal:  Environ Health Perspect       Date:  1997-09       Impact factor: 9.031

6.  Associations among lead dose biomarkers, uric acid, and renal function in Korean lead workers.

Authors:  Virginia M Weaver; Bernard G Jaar; Brian S Schwartz; Andrew C Todd; Kyu-Dong Ahn; Sung-Soo Lee; Jiayu Wen; Patrick J Parsons; Byung-Kook Lee
Journal:  Environ Health Perspect       Date:  2005-01       Impact factor: 9.031

7.  Neuroprotective Actions of Clinoptilolite and Ethylenediaminetetraacetic Acid Against Lead-induced Toxicity in Mice Mus musculus.

Authors:  Mahaboob P Basha; Shabana Begum; Bilal Ahmed Mir
Journal:  Toxicol Int       Date:  2013-09

8.  Metabolic profiling of metformin treatment for low-level Pb-induced nephrotoxicity in rat urine.

Authors:  Yu-Shen Huang; Shwu-Huey Wang; Shih-Ming Chen; Jen-Ai Lee
Journal:  Sci Rep       Date:  2018-10-01       Impact factor: 4.379

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.